Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.33 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31409894 | 1.00 | MGAM (0.38) | MGAMSMYD2GAASIGMAR1GBA1 | |
| SCHEMBL17894245 | 1.00 | MGAM (0.38) | MGAMSMYD2GAASIGMAR1GBA1 | |
| SCHEMBL15872554 | 0.88 | SIGMAR1 (0.37) | MGAMGAASIGMAR1GBA1DRD2 | |
| SCHEMBL17895160 | 0.82 | SMYD2 (0.38) | MGAMSMYD2 | |
| SCHEMBL18170201 | 0.81 | DRD2 (0.39) | MGAMSMYD2GAASIGMAR1GBA1 | |
| SCHEMBL17005443 | 0.81 | SIGMAR1 (0.44) | SIGMAR1GBA1DRD2DRD3 | |
| SCHEMBL7328073 | 0.79 | MAPT (0.40) | MGAMSMYD2SIGMAR1GBA1 | |
| SCHEMBL10417697 | 0.79 | MAPT (0.40) | MGAMSMYD2SIGMAR1GBA1 | |
| SCHEMBL14636816 | 0.79 | SRC (0.38) | SMYD2 | |
| SCHEMBL17895054 | 0.79 | SRC (0.38) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | MGAM 3376/4885SMYD2 2906/4885GAA 1142/4885 |
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | MGAM 2315/4885SMYD2 1706/4885GAA 993/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | MGAM 2315/4885SMYD2 1706/4885GAA 993/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | MGAM 3552/4885SMYD2 2857/4885GAA 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.